Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP)

Drapkina, О. М.; Карпов, О Э; Loukyanov, M.M.; Martsevich, S. Yu.; Пулин, А А; Кутишенко, Н. П.; Акимкин, В. Г.; Andreenkо, E. Yu.; Воронина, В. П.; Dindikova, V. A.; Дмитриева, Н. А.; Zagrebelnyy, A. V.; Лерман, О. В.; Makoveeva, A. N.; Okshina, Е. Yu.; Kudryashov, E. V.; Klyashtorniy, V.G.; Smirnov, A. A.; Fomina, V.S.

doi:10.17116/profmed2020230816

Cited by 17 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В регистре ТАРГЕТ-ВИП наиболее часто для лечения COVID-19 назначались гидроксихлорохин, азитромицин или другие антибиотики, антитромботические препараты и глюкокортикостероиды [11], что согласуется с нашими данными, за исключением назначения гидроксихлорохина. Следует особо отметить, что антикоагулянты были назначены больным с сердечно-сосудистыми заболеваниями в 84,1% случаев, однако столь высокая частота их использования обусловлена в большинстве случаев не наличием кардиоваскулярной патологии, в т.ч.…”

Section: Discussionunclassified

Charlson comorbidity index in predicting deaths in COVID-19 patients

Svarovskaya

Shabelsky²,

Levshin³

2022

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To assess the clinical performance and factors associated with inhospital mortality in patients with coronavirus disease 2019 (COVID-19).Material and methods. Our results are based on data from hospital charts of inpatients hospitalized in the Asinovskaya District Hospital in the period from March 11, 2020 to December 31, 2020, with a verified COVID-19 by polymerase chain reaction. The study included 151 patients, the median age of which was 66,2 (50- 92) years (women, 91; 60,3%). The study endpoints were following hospitalization outcomes: discharge or death. Depending on the outcomes, the patients were divided into 2 groups: the 1st group included 138 patients (survivors), while the 2nd one included 13 patients (death). To objectify the severity of multimorbidity status, the Charlson comorbidity index was used. The final value was estimated taking into account the patient age by summing the points assigned to a certain nosological entity using a calculator table.Results. Hypertension was recorded in the majority of patients — 79,5%, chronic kidney disease — in 61,1%. The prevalence of type 2 diabetes and coronary artery disease was high — 31,8% each. Prior myocardial infarction was diagnosed in 11,3% of cases. The prevalence of percutaneous coronary intervention and coronary bypass surgery was 5,3% and 3,3%, respectively. Stroke was detected in 9,3% of participants. Prior chronic pulmonary pathologies in COVID-19 patients were rare (asthma — 3,3%, chronic obstructive pulmonary disease — 2,0%). In order to predict the death risk in COVID-19 patients, a logistic regression analysis was performed, which showed that age and Charlson comorbidity index were the most significant predictors.Conclusion. Independent factors of inhospital mortality were age and Charlson’s comorbidity index. The risk assessment model will allow clinicians to identify patients with a poor prognosis at an earlier disease stage, thereby reducing mortality by implementing more effective COVID-19 treatment strategies in conditions with limited medical resources.

show abstract

Section: Discussionunclassified

Charlson comorbidity index in predicting deaths in COVID-19 patients

Svarovskaya

Shabelsky²,

Levshin³

2022

Russ J Cardiol

View full text Add to dashboard Cite

show abstract

“…Для анализа наличия ХСН у пациентов после COVID-19 была сформирована выборка пациентов из регистра ТАРГЕТ-ВИП (ПроспекТивный госпитАльный РеГистр пациЕнТов с предполагаемыми, либо подтвержденными коронаВИрусной инфекцией (COVID-19) и внебольничной Пневмонией) (n=1130) [5]. В регистр ТАРГЕТ-ВИП были последовательно включены пациенты, поступившие в НМХЦ им.…”

Section: материал и методыunclassified

“…Н. И. Пирогова с подозрением на COVID-19 в период с 06.04.2020г по 02.07.2020г. Подробно дизайн исследования ТАРГЕТ-ВИП был описан ранее [5,6]. Из них были отобраны 792 пациента, выписанных из стационара и проживавших в Москве или Московской области, с которыми удалось связаться через 12 мес.…”

Section: материал и методыunclassified

Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization

Mareev¹,

Lukyanov²,

Martsevich³

et al. 2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To estimate the detection rate of heart failure (HF), using various diagnosis criteria, among patients aftr 12 months after hospital treatment for coronavirus disease 2019 (COVID-19).Material and methods. The study included 185 patients from the TARGET-VIP registry who came for a visit 12 months after hospitalization for COVID-19. To identify HF with reduced (HFrEF) and mildly reduced (HFmrEF) ejection fraction (EF), the European Society of Cardiology (ESC) criteria (2016 and 2021) were used. To identify HF with preserved EF (HFpEF), we used the ESC criteria (2016 and 2021), as well as the 2018 Russian guidelines and H2FPEF score.Results. In the analyzed group, there were no patients with EF <40%, while one patient had EF of 48% and 184 patients — ≥50%. The patient with EF of 48% was not diagnosed with HF due to the absence of HF signs and symptoms. The presence of HFpEF was confirmed in 31,4% of patients according to 2018 Russian criteria and 2021 ESC criteria (first version of the diagnosis), in 12,5% according to the 2016 ESC criteria, 11% according to ESC 2021 criteria (second version of the diagnosis) and in 2,2% on the H2FPEF score. The proportion of HF diagnosed for the first time according to the 2016 ESC criteria was 78% of the total number of HF cases.Conclusion. Among the examined patients 12 months after hospital treatment for COVID-19, there were no cases of HFrEF and HFmrEF. The proportion of HFpEF cases, depending on the diagnostic criteria used, varied significantly from 2,2 to 31,4%. The previously established diagnosis of HF was confirmed in 83% of cases at a visit 12 months after discharge from the hospital. Using the 2016 ESC criteria and the corresponding 2020 Russian Society of Cardiology guidelines, the proportion of newly diagnosed HF was 78% of all patients.

show abstract

“…One of the consequences of COVID-19 is the so-called post-COVID syndrome. Clinical manifestations and features of the pathogenesis of this condition are being actively studied; no specific methods of prevention and treatment have been developed thus far [ 44 ]. Post-COVID complications and deviations are manifested in the activity of various organs and systems, primarily respiratory, cardiovascular, and nervous.…”

mentioning

confidence: 99%

“…The prospective TARGET-VIP registry was formed at the National Medical Research Center for Therapy and Preventive Medicine, which included 1130 patients with COVID-19 and/or community-acquired pneumonia hospitalized during the first epidemic wave at the Pirogov National Medical and Surgical Center (headed by RAS Corresponding Member O.E. Karpov) [ 44 ]. According to the registry, within the epidemic wave, a weekly increase in the age of hospitalized patients with the new coronavirus infection was revealed, as well as the proportion of cases of concomitant cardiovascular diseases and/or chronic noncardiac pathology.…”

mentioning

confidence: 99%

Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection

Драпкина

Yavelov

2022

Her. Russ. Acad. Sci.

View full text Add to dashboard Cite

The means of drug intervention for the prevention and treatment of new coronavirus infection (COVID-19) are discussed. Changes in approaches aimed at the main links of pathogenesis and capable of positively influencing the course and outcome of the disease that have been implemented after the appearance of the results of numerous randomized trials are presented. Some aspects of the ongoing study of the problem are characterized.

show abstract

Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP)

Cited by 17 publications

References 15 publications

Charlson comorbidity index in predicting deaths in COVID-19 patients

Charlson comorbidity index in predicting deaths in COVID-19 patients

Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization

Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection

Contact Info

Product

Resources

About